• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

18F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描中最大标准化摄取值在骨肉瘤中的预后意义

Prognostic significance of maximum standardized uptake value on 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in bone sarcomas.

作者信息

Tamam Cüneyt, Tamam Müge

机构信息

Department of Orthopedics and Traumatology, Specialist Private Practice, İstanbul, Turkey.

出版信息

Eklem Hastalik Cerrahisi. 2018 Dec;29(3):184-8. doi: 10.5606/ehc.2018.60419.

DOI:10.5606/ehc.2018.60419
PMID:30376804
Abstract

OBJECTIVES

This study aims to evaluate the prognostic significance of maximum standardized uptake value (SUVmax) on 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) for bone sarcoma.

PATIENTS AND METHODS

We retrospectively evaluated 34 patients (24 males, 10 females; mean age 36.6±24.2 years; range, 5 to 77 years) with pathologically proven bone sarcoma who underwent 18FDG-PET/CT for initial staging between September 2013 and September 2017. SUVmax of primary lesions were measured. Cumulative survival rate was calculated to evaluate the prognostic value of 18FDG-PET/CT findings. Survival duration was defined as the elapsed duration from the date of pre-treatment 18FDG-PET/CT scanning until the date of the final examination before the date of death.

RESULTS

The cut-off value for SUVmax in the definition of progression was 8. Mean SUVmax of the progressive group was statistically significantly higher than the non-progressive group. Distant metastases were present in 14 (41.1%) cases. Mortality and cumulative survival rates were 14.7% and 79.1±0.08%, respectively.

CONCLUSION

Semiquantitative estimation of primary tumor metabolic activity in terms of baseline SUVmax using 18FDG-PET/CT can predict the overall survival of patients with bone sarcoma.

摘要

目的

本研究旨在评估18F-氟-2-脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18FDG-PET/CT)中最大标准化摄取值(SUVmax)对骨肉瘤的预后意义。

患者与方法

我们回顾性评估了2013年9月至2017年9月期间34例经病理证实的骨肉瘤患者(24例男性,10例女性;平均年龄36.6±24.2岁;范围5至77岁),这些患者因初始分期接受了18FDG-PET/CT检查。测量了原发灶的SUVmax。计算累积生存率以评估18FDG-PET/CT检查结果的预后价值。生存时间定义为从治疗前18FDG-PET/CT扫描日期到死亡日期前最后一次检查日期的 elapsed duration。

结果

进展定义中SUVmax的临界值为8。进展组的平均SUVmax在统计学上显著高于非进展组。14例(41.1%)出现远处转移。死亡率和累积生存率分别为14.7%和79.1±0.08%。

结论

使用18FDG-PET/CT根据基线SUVmax对原发肿瘤代谢活性进行半定量评估可预测骨肉瘤患者的总生存期。

相似文献

1
Prognostic significance of maximum standardized uptake value on 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in bone sarcomas.18F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描中最大标准化摄取值在骨肉瘤中的预后意义
Eklem Hastalik Cerrahisi. 2018 Dec;29(3):184-8. doi: 10.5606/ehc.2018.60419.
2
Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?[F-18]氟脱氧-D-葡萄糖正电子发射断层扫描在接受新辅助治疗的颅面骨肉瘤患者的管理中是否有价值?
BMC Cancer. 2014 Jan 15;14:23. doi: 10.1186/1471-2407-14-23.
3
Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.比较⁹⁹ᵐTc-亚甲基二膦酸盐骨闪烁显像与¹⁸F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在预测骨肉瘤患者新辅助化疗组织学反应中的应用
Medicine (Baltimore). 2018 Sep;97(37):e12318. doi: 10.1097/MD.0000000000012318.
4
The Utility of 18FDG PET/CT Versus Bone Scan for Identification of Bone Metastases in a Pediatric Sarcoma Population and a Review of the Literature.18FDG PET/CT 与骨扫描在儿科肉瘤患者骨转移中的应用价值:文献复习
J Pediatr Hematol Oncol. 2021 Mar 1;43(2):52-58. doi: 10.1097/MPH.0000000000001917.
5
Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.治疗前氟-18氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描测量的SUVmax对尤因肉瘤患者的预后价值
PLoS One. 2016 Apr 21;11(4):e0153281. doi: 10.1371/journal.pone.0153281. eCollection 2016.
6
Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.正电子发射断层扫描/计算机断层扫描(PET/CT)成像在肉瘤评估中的应用:系统评价。
Crit Rev Oncol Hematol. 2019 Nov;143:1-13. doi: 10.1016/j.critrevonc.2019.07.002. Epub 2019 Jul 21.
7
SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer.(18)氟-脱氧葡萄糖正电子发射断层扫描/计算机断层扫描后的 SUVmax:一种用于定义胰腺癌治疗策略的工具。
Dig Liver Dis. 2018 Jan;50(1):84-90. doi: 10.1016/j.dld.2017.09.122. Epub 2017 Sep 22.
8
Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas.18F氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在儿童肉瘤分期中的准确性
J Pediatr Hematol Oncol. 2007 Sep;29(9):608-12. doi: 10.1097/MPH.0b013e318142b5ab.
9
Prognostic significance of standardised uptake value (SUV ) measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描测量的标准化摄取值(SUV)在小细胞肺癌患者中的预后意义
Eur J Cancer Care (Engl). 2017 Sep;26(5). doi: 10.1111/ecc.12485. Epub 2016 Mar 14.
10
The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描(FDG PET/CT)在局部骨肉瘤新辅助化疗患者中的作用
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):215-223. doi: 10.1007/s00259-016-3509-z. Epub 2016 Sep 20.

引用本文的文献

1
Prognostic significance of the preoperative neutrophil-to-lymphocyte ratio patients with giant cell tumor of bone.术前中性粒细胞与淋巴细胞比值对骨巨细胞瘤患者的预后意义。
Afr Health Sci. 2021 Sep;21(3):1250-1258. doi: 10.4314/ahs.v21i3.35.
2
Diagnostic role of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in patients with enchondroma and low-grade chondrosarcoma.中性粒细胞与淋巴细胞比值及单核细胞与淋巴细胞比值在内生软骨瘤和低级别软骨肉瘤患者中的诊断作用
Jt Dis Relat Surg. 2020;31(2):286-290. doi: 10.5606/ehc.2020.73629. Epub 2020 Jun 18.